Fluoro AChE
- Known as:
- Fluoro AChE
- Catalog number:
- AChE100-2
- Product Quantity:
- 100 tests
- Category:
- -
- Supplier:
- Celleng-tech
- Gene target:
- Fluoro AChE
Related genes to: Fluoro AChE
- Gene:
- ACHE NIH gene
- Name:
- acetylcholinesterase (Cartwright blood group)
- Previous symbol:
- YT
- Synonyms:
- -
- Chromosome:
- 7q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-02
- Date modifiied:
- 2019-04-23
Related products to: Fluoro AChE
(+)-5-Fluoro-2'-deoxyuridine (+)-5-Fluoro-2'-deoxyuridine For research use only.(-)-β-D-Dioxolane-5-fluoro Cytidine C8H10FN3O4 CAS: 145397-26-8(-)-β-D-Dioxolane-5-fluoro Cytidine CAS: 145397-26-8 Formula: C8H10FN3O4(11β)-21-Chloro-9-fluoro-11-hydroxy-16-methylpregna-1,4,16-triene-3,20-dione C22H26ClFO3 CAS: 1356190-17-4(11β)-21-Chloro-9-fluoro-11-hydroxy-16-methylpregna-1,4,16-triene-3,20-dione CAS: 1356190-17-4 Formula: C22H26ClFO3(11β,16α)-21-(Acetyloxy)-9-fluoro-11,16,17-trihydroxy-pregna-1,4,14-triene-3,20-dione C23H27FO7 CAS: 131918-74-6(11β,16α)-21-(Acetyloxy)-9-fluoro-11,16,17-trihydroxy-pregna-1,4,14-triene-3,20-dione CAS: 131918-74-6 Formula: C23H27FO7(11β,16α)-9-Fluoro-11,16,17,21-tetrahydroxy-pregna-1,4-diene-3,20-dione-d2 3,20-Dioxime C21H27D2FN2O6 CAS:(11β,16α)-9-Fluoro-11,16,17,21-tetrahydroxy-pregna-1,4-diene-3,20-dione-d2 3,20-Dioxime CAS: Formula: C21H27D2FN2O6(11β,16α)-9-Fluoro-11,21,21-trihydroxy-16,17-[(1-methylethylidene)bis(oxy)]
pregna-1,4-diene-3,20-dione CAS: 161740-69-8 Formula: C24H31FO7(11β,16α)-9-Fluoro-16,17,21-trihydroxyl-pregna-1,4-diene-3,11,20-trione 3,20-Dioxime C21H27FN2O6 CAS:(11β,16α)-9-Fluoro-16,17,21-trihydroxyl-pregna-1,4-diene-3,11,20-trione 3,20-Dioxime CAS: Formula: C21H27FN2O6(11β,16α,20R)-9-Fluoro-11,20-dihydroxy-16-methyl-3-oxopregna-1,4-dien-21-oic Acid C22H29FO5 CAS: 50764-01-7(11β,16α,20R)-9-Fluoro-11,20-dihydroxy-16-methyl-3-oxopregna-1,4-dien-21-oic Acid CAS: 50764-01-7 Formula: C22H29FO5(11β,16α,20S)-9-Fluoro-11,20-dihydroxy-16-methyl-3-oxopregna-1,4-dien-21-oic Acid C22H29FO5 CAS: 50764-02-8 Related articles to: Fluoro AChE
- - Source: PubMed
Publication date: 2026/06/13
Berggren Carolyn CParajuli AnupaButt Amir LZhong John - To evaluate the effects of perioperative music interventions on emotional outcomes (preoperative anxiety, postoperative fear, emergence delirium) and related physiological parameters in children and adolescents undergoing surgery, and to examine potential effect modifiers. - Source: PubMed
Publication date: 2026/06/13
Wen YuchenHan JinyingGao JiayinLou JiaqiXiang Ziyi - The aim of this study is to compare the clinical efficacy and safety of platelet-rich plasma (PRP) and hyaluronic acid in the treatment of hip osteoarthritis. - Source: PubMed
Zhang DiMa Shen HongWang He LingHan Qiao HuaShen KaiZhuang Weisheng - Intrauterine adhesions (IUA) and endometriosis are debilitating gynecological disorders that impair endometrial function and fertility. IUA, typically caused by iatrogenic trauma to the basal endometrium, leads to fibrosis and infertility, whereas endometriosis, characterized by ectopic endometrial growth, induces chronic inflammation, pain, and subfertility. Current treatments, such as surgical adhesiolysis for IUA and hormonal suppression for endometriosis, frequently fail to address underlying pathological mechanisms, including aberrant fibrosis, inflammatory cascades, and impaired tissue regeneration. Recently, mesenchymal stem cells (MSCs) have emerged as a promising therapeutic approach. Their therapeutic benefits are mediated primarily through paracrine actions, which modulate immune responses, promote tissue repair, and attenuate inflammation and fibrosis. Recent studies have further highlighted the potential of MSC-derived exosomes (MSC-Exos) as a cell-free alternative. In this review, we comprehensively summarize current evidence from animal models and clinical studies on the application of MSCs and MSC-Exos in treating IUA and endometriosis, focusing on their therapeutic potential, mechanisms of action, and future directions. We also discuss remaining challenges and promising strategies to overcome them, thereby positioning MSC-based therapies as transformative options for endometrial restoration and disease management. - Source: PubMed
Liu Si-HanHe Shu-YangJi Bing-QianZhang Xiang-ChengLi Jing-YuanLiu Quan-Wen - Gout is a metabolic disorder caused by abnormalities in purine metabolism and/or impaired uric acid excretion. It is characterized by the deposition of monosodium urate crystals in joints or connective tissues, leading to recurrent episodes of acute arthritis. Gout can be categorized into two major types based on its etiology: primary and secondary. The majority of gout cases are associated with impaired uric acid excretion. The natural course of gout can be divided into three stages: (1) asymptomatic phase; (2) acute arthritis phase and intercritical phase; (3) chronic gouty arthritis and tophaceous phase. Acute gouty arthritis typically presents with sudden, severe joint pain, accompanied by redness, swelling, warmth, and tenderness of the affected joint and surrounding soft tissues. When large joints are involved, joint effusion may occur. Acute gouty arthritis often develops at night or in the early morning, is self-limiting, and usually resolves within two weeks. The most common site of acute gout flare-ups is the first metatarsophalangeal joint, followed by the midfoot, ankle, knee, wrist, fingers, and elbow joints. Acute gout attacks rarely affect the axial joints. Pain in these affected areas is often accompanied by limited function, significantly impacting a patient' s daily activities and quality of life. Uncommon sites of gout involvement, as well as gout with normal serum uric acid levels, can easily lead to misdiagnosis. Therefore, a comprehensive diagnosis requires a detailed medical history, physical examination, laboratory tests, and imaging studies. This case report describes a 19-year-old male who was admitted with recurrent anterior chest pain. The diagnosis at another hospital suggested ankylosing spondylitis. Physical examination revealed significant tenderness, redness, and swelling of the bilateral sternoclavicular joints, with local warmth and mildly restricted movement. MRI of the sacroiliac joints showed no significant abnormalities, and serum uric acid levels were normal. Chest dual-energy CT scans revealed multiple tophi in the sternum, bilateral clavicles, scapulae, multiple ribs, and along the edges of the sternum. Based on the patient' s medical history, physical findings, and imaging studies, a diagnosis of gout was confirmed. Treatment included urate-lowering therapy, pain management, and dietary adjustments. During a two-year follow-up period, the patient did not experience recurrent anterior chest pain, and multiple serum uric acid tests consistently showed levels below 300 μmol/L. Repeat chest dual-energy CT scans indicated significant reduction of tophi in the sternoclavicular joints and other affected areas. - Source: PubMed
Gan DiFu QiangTang XiaohuiLi ChuweiShu Zhaoping